Scholarlink

<p>This study aimed to evaluate the impact of digestive and bladder positive contrast agents (CA) on radiation dose and cancer risk during pelvic computed tomography (CT) scans using Monte Carlo simulation with the GATE platform and computational phantoms. The Siemens Emotion 16-slice CT scanner model was validated by comparing measured and simulated CTDI<sub>vol</sub> values using pelvic CT parameters. The densities and chemical compositions of CAs (Gastrografin<sup>®</sup> 30% and Utravist<sup>®</sup> 30%) were incorporated into the bladder and rectal cavities of Female Adult mesh (FASH) and Male Adult mesh (MASH) phantoms. Organ doses were simulated for scenarios using bladder CA (D<sub>U</sub>), digestive CA (D<sub>D</sub>), and both CAs (D<sub>DU</sub>). The dose enhancement factor (DEF) and lifetime attributable risk (LAR) were calculated using the Biological Effects of Ionizing Radiation (BEIR) VII model, considering a reference age of 30 years.The highest effective dose was observed in females (4.83 mSv) compared to males (2.61 mSv). The small intestine (22.35 mGy) and uterus (27.64 mGy) recorded the highest absorbed doses. Positive CAs significantly reduced radiation dose and cancer risk, with the greatest reductions achieved when both CAs were applied (mean DEF<sub>DU</sub>,male = 0.68, mean DEF<sub>D</sub>,male = 0.75, DEF<sub>U,</sub>male = 0.90). Specific reductions were noted for Organs containing CA, including the bladder (DEF<sub>DU</sub>,male = 0.41, DEF<sub>DU</sub>,female = 0.55) and small intestine (DEF<sub>DU</sub>,male = 0.52, DEF<sub>DU</sub>,female = 0.53). Cancer risk reductions ranged from 8.84% to 38.86% in females and 5.24% to 33.65% in males, with reductions of 19.59% for the uterus, 29.20% for the ovaries, and 40.84% for the prostate.The shadowing effect of enhanced cavities demonstrated a significant reduction in radiation dose and cancer risk, highlighting potential applications of CAs in clinical practice to improve safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Monte Carlo simulation of digestive and bladder positive contrast in pelvic CT scan examination: radiation dose and cancer risk assessment

  • 期刊论文

  • 发表日期：

    2025年12月3日

查看全文
  • Maroine Tahiri,
  • Yassine Benameur,
  • Mina Azeddou,
  • Redouane El baydaoui,
  • Aziz Elkhatib,
  • Noureddine Elamri,
  • Mounir Mkimel

摘要

This study aimed to evaluate the impact of digestive and bladder positive contrast agents (CA) on radiation dose and cancer risk during pelvic computed tomography (CT) scans using Monte Carlo simulation with the GATE platform and computational phantoms. The Siemens Emotion 16-slice CT scanner model was validated by comparing measured and simulated CTDIvol values using pelvic CT parameters. The densities and chemical compositions of CAs (Gastrografin® 30% and Utravist® 30%) were incorporated into the bladder and rectal cavities of Female Adult mesh (FASH) and Male Adult mesh (MASH) phantoms. Organ doses were simulated for scenarios using bladder CA (DU), digestive CA (DD), and both CAs (DDU). The dose enhancement factor (DEF) and lifetime attributable risk (LAR) were calculated using the Biological Effects of Ionizing Radiation (BEIR) VII model, considering a reference age of 30 years.The highest effective dose was observed in females (4.83 mSv) compared to males (2.61 mSv). The small intestine (22.35 mGy) and uterus (27.64 mGy) recorded the highest absorbed doses. Positive CAs significantly reduced radiation dose and cancer risk, with the greatest reductions achieved when both CAs were applied (mean DEFDU,male = 0.68, mean DEFD,male = 0.75, DEFU,male = 0.90). Specific reductions were noted for Organs containing CA, including the bladder (DEFDU,male = 0.41, DEFDU,female = 0.55) and small intestine (DEFDU,male = 0.52, DEFDU,female = 0.53). Cancer risk reductions ranged from 8.84% to 38.86% in females and 5.24% to 33.65% in males, with reductions of 19.59% for the uterus, 29.20% for the ovaries, and 40.84% for the prostate.The shadowing effect of enhanced cavities demonstrated a significant reduction in radiation dose and cancer risk, highlighting potential applications of CAs in clinical practice to improve safety.